Corporate Symposia

Corporate Symposia

*Lunch will be provided to the session attendees (marked with* below)

Friday, October 18, 2024

Corporate Symposium (CS01) | Servier*

Multidisciplinary clinical management of diffuse glioma patients: Is it still the era of watch & wait?

 

Friday, October 18, 13:30 - 14:30 hrs, M1

13:30 – 13:40

Welcome & Introduction

Welcome; Essentials on diffuse glioma management; Overview of the program

Matthias Preusser, Austria

13:40 – 13:50

The Neurosurgeon Perspective: Why and how going beyond surgery?

Joerg Tonn, Germany

13:50 – 14:00

The Psychologist Perspective: How much quality-of-life matters, and can we achieve shared-decision making?.

Florien Boele, United Kingdom

14:00 – 14:10

The Patient Perspective: How can we express our considerations and develop our abilities to act empowerment?

Donald Innes, United Kingdom

14:10 – 14:25

 Panel Discussion/Q&A

All Faculty members
14:25 – 14:30

 Conclusion

James Perry, Canada

 


Corporate Symposium (CS02) | Novocure* (not intended for US healthcare professionals)

Real World Evidence: 10 Years of Experience Treating High Grade Glioma with Tumor Treating Fields (TTFields) Therapy

Friday, October 18, 13:30- 14:30 hrs, Alsh

13:30 – 13:35

Welcome & Introduction

Luis Castelo-Branco, Switzerland

13:35 – 13:45

Relevance of Real-World Evidence (RWE)

Luis Castelo-Branco, Switzerland

13:45 – 13:55

Introduction to TTFields & RWE Data

Matthew Williams, United Kingdom

13:55 – 14:10

The TIGER Experience

Oliver Bär, Germany
14:10 – 14:20Importance of RWE to a Regulatory Perspective
Luis Castelo-Branco, Switzerland
14:20 – 14:30Closing and Q&A
All

 

Saturday, October 19, 2024

Corporate Symposium (CS03) | Imvax*

Development of IGV-001 for the treatment of newly diagnosed glioblastoma

Saturday, October 19, 13:00 - 14:00 hrs, M1

13:00 – 13:05

Welcome and introductions

Raul Perez-Olle, United States

13:05 – 13:15

Imvax overview. The GoldspireTM platform.

Raul Perez-Olle, United States

13:15 – 13:30

Early development of IGV-001 in glioblastomaTreatment Landscape

Soma Sengupta, United States

13:30 – 13:50

Phase 2b study of IGV-001 in newly diagnosed glioblastoma

Simon Hanft, United States

13:50 – 14:00

Q&A

 


Corporate Symposium (CS04) | Medtronic

LITT* as a surgical minimally invasive treatment option in neuro-oncology

(*Laser Interstitial Thermal Therapy)

Saturday, October 19, 13:00 - 13:30 hrs, Alsh

Chairs: Jiri Bartek, Margret Jensdottir

13:00 – 13:15

Basic overview of LITT procedure for treating brain tumours, patient selection and literature overview

Jiri Bartek, Sweden
13:15 – 13:25

Clinical experience with LITT and case presentation

Margret Jensdottir, Sweden

13:25 – 13:30

Questions & Answers